Phage therapy in noncommunicable diseases

Denise Kviatcovsky,Rafael Valdés-Mas,Sara Federici,Eran Elinav

DOI: https://doi.org/10.1126/science.adh2718

IF: 56.9

2023-10-21

Science

Abstract:Bacteriophages have potential as suppressors of disease-contributing commensal bacteria

multidisciplinary sciences

What problem does this paper attempt to address?

Thromboxane a2: biosynthesis and effects on platelets.

E. Granström,U. Diczfalusy,M. Hamberg,G. Hansson,C. Malmsten,B. Samuelsson

Abstract:
Phage Therapy: A Different Approach to Fight Bacterial Infections

Yibeltal Akelew,H. M. Mengist,Habtamu Belew,Zigale Hibstu

Abstract:: Phage therapy is one of the alternatives to treat infections caused by both antibiotic-sensitive and antibiotic-resistant bacteria, with no or low toxicity to patients. It was started a century ago, although rapidly growing bacterial antimicrobial resistance, resulting in high levels of morbidity, mortality, and financial cost, has initiated the revival of phage therapy. It involves the use of live lytic, bioengineered, phage-encoded biological products, in combination with chemical antibiotics to treat bacterial infections. Importantly, phages will be removed from the body within seven days of clearing an infection. They target specific bacterial strains and cause minimal disruption to the microbial balance in humans. Phages for medication must be screened for the absence of resistant genes, virulent genes, cytotoxicity, and their interaction with the host tissue and organs. Since they are immunogenic, applying a high phage titer for therapy exposes them and activates the host immune system. To date, no serious side effects have been reported with human phage therapy. In this review, we describe phage–phagocyte interaction, bacterial resistance to phages, how phages conquer bacterial resistance, the role of genetic engineering and other technologies in phage therapy, and the therapeutic application of modified phages and phage-encoded products. We also highlight the comparison of antibiotics and lytic phage therapy, the pros and cons of phage therapy, determinants of human phage therapy trials, phage quality and safety requirements, phage storage and handling, and current challenges in phage therapy.

Biology,Medicine
Phage therapy in gut microbiome

Xingyao Chen,Beatriz G Mendes,Bruno Secchi Alves,Yi Duan

DOI: https://doi.org/10.1016/bs.pmbts.2023.04.005

Abstract:Phage therapy, the use of bacteriophage viruses for bacterial infection treatment, has been around for almost a century, but with the increase in antibiotic use, its importance has declined rapidly. There has been renewed interest in revisiting this practice due to the general decline in the effectiveness of antibiotics, combined with improved understanding of human microbiota and advances in sequencing technologies. Phage therapy has been proposed as a clinical alternative to restore the gut microbiota in the absence of an effective treatment. That is due to its immunomodulatory and bactericidal effects against its target bacteria. In the gastrointestinal diseases field, phage therapy has been studied mainly as a promising tool in infectious diseases treatment, such as cholera and diarrhea. However, many studies have been conducted in non-communicable diseases, such as the targeting of adherent invasive Escherichia coli in Crohn's disease, the treatment of Clostridioides difficile in ulcerative colitis, the eradication of Fusobacterium nucleatum in colorectal cancer, the targeting of alcohol-producing Klebsiella pneumoniae in non-alcoholic fatty liver disease, or Enterococcus faecalis in alcohol-associated hepatitis. This review will summarize the changes in the gut microbiota and the phageome in association with some gastrointestinal and liver diseases and highlight the recent scientific advances in phage therapy as a therapeutic tool for their treatment.
Phage therapy: From biological mechanisms to future directions

Steffanie A. Strathdee,Graham F. Hatfull,Vivek K. Mutalik,Robert T. Schooley

DOI: https://doi.org/10.1016/j.cell.2022.11.017

IF: 64.5

2023-01-06

Cell

Abstract:Increasing antimicrobial resistance rates have revitalized bacteriophage (phage) research, the natural predators of bacteria discovered over 100 years ago. In order to use phages therapeutically, they should (1) preferably be lytic, (2) kill the bacterial host efficiently, and (3) be fully characterized to exclude side effects. Developing therapeutic phages takes a coordinated effort of multiple stakeholders. Herein, we review the state of the art in phage therapy, covering biological mechanisms, clinical applications, remaining challenges, and future directions involving naturally occurring and genetically modified or synthetic phages.

cell biology,biochemistry & molecular biology
Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation

Sara Federici,Sharon Kredo-Russo,Rafael Valdés-Mas,Denise Kviatcovsky,Eyal Weinstock,Yulia Matiuhin,Yael Silberberg,Koji Atarashi,Munehiro Furuichi,Akihiko Oka,Bo Liu,Morine Fibelman,Iddo Nadav Weiner,Efrat Khabra,Nyssa Cullin,Noa Ben-Yishai,Dana Inbar,Hava Ben-David,Julian Nicenboim,Noga Kowalsman,Wolfgang Lieb,Edith Kario,Tal Cohen,Yael Friedman Geffen,Lior Zelcbuch,Ariel Cohen,Urania Rappo,Inbar Gahali-Sass,Myriam Golembo,Vered Lev,Mally Dori-Bachash,Hagit Shapiro,Claudia Moresi,Amanda Cuevas-Sierra,Gayatree Mohapatra,Lara Kern,Danping Zheng,Samuel Philip Nobs,Jotham Suez,Noa Stettner,Alon Harmelin,Naomi Zak,Sailaja Puttagunta,Merav Bassan,Kenya Honda,Harry Sokol,Corinna Bang,Andre Franke,Christoph Schramm,Nitsan Maharshak,Ryan Balfour Sartor,Rotem Sorek,Eran Elinav

DOI: https://doi.org/10.1016/j.cell.2022.07.003

IF: 64.5

2022-08-06

Cell

Abstract:Human gut commensals are increasingly suggested to impact non-communicable diseases, such as inflammatory bowel diseases (IBD), yet their targeted suppression remains a daunting unmet challenge. In four geographically distinct IBD cohorts (n = 537), we identify a clade of Klebsiella pneumoniae (Kp) strains, featuring a unique antibiotics resistance and mobilome signature, to be strongly associated with disease exacerbation and severity. Transfer of clinical IBD-associated Kp strains into colitis-prone, germ-free, and colonized mice enhances intestinal inflammation. Stepwise generation of a lytic five-phage combination, targeting sensitive and resistant IBD-associated Kp clade members through distinct mechanisms, enables effective Kp suppression in colitis-prone mice, driving an attenuated inflammation and disease severity. Proof-of-concept assessment of Kp-targeting phages in an artificial human gut and in healthy volunteers demonstrates gastric acid-dependent phage resilience, safety, and viability in the lower gut. Collectively, we demonstrate the feasibility of orally administered combination phage therapy in avoiding resistance, while effectively inhibiting non-communicable disease-contributing pathobionts.

cell biology,biochemistry & molecular biology
Bacteriophages as Alternatives to Antibiotics in Clinical Care

Danitza Romero-Calle,Raquel Guimarães Benevides,Aristóteles Góes-Neto,Craig Billington

DOI: https://doi.org/10.3390/antibiotics8030138

2019-09-04

Antibiotics

Abstract:Antimicrobial resistance is increasing despite new treatments being employed. With a decrease in the discovery rate of novel antibiotics, this threatens to take humankind back to a “pre-antibiotic era” of clinical care. Bacteriophages (phages) are one of the most promising alternatives to antibiotics for clinical use. Although more than a century of mostly ad-hoc phage therapy has involved substantial clinical experimentation, a lack of both regulatory guidance standards and effective execution of clinical trials has meant that therapy for infectious bacterial diseases has yet to be widely adopted. However, several recent case studies and clinical trials show promise in addressing these concerns. With the antibiotic resistance crisis and urgent search for alternative clinical treatments for bacterial infections, phage therapy may soon fulfill its long-held promise. This review reports on the applications of phage therapy for various infectious diseases, phage pharmacology, immunological responses to phages, legal concerns, and the potential benefits and disadvantages of this novel treatment.
Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens

Heba Mohammed Refat M Selim,Fatma Alzahraa M Gomaa,Mohammad Y Alshahrani,Radwa N Morgan,Khaled M Aboshanab

DOI: https://doi.org/10.1080/20415990.2024.2426824

2024-11-15

Abstract:The ongoing global health crisis caused by multidrug-resistant (MDR) bacteria necessitates quick interventions to introduce new management strategies for MDR-associated infections and antimicrobial agents' resistance. Phage therapy emerges as an antibiotic substitute for its high specificity, efficacy, and safety profiles in treating MDR-associated infections. Various in vitro and in vivo studies denoted their eminent bactericidal and anti-biofilm potential. This review addresses the latest developments in phage therapy regarding their attack strategies, formulations, and administration routes. It additionally discusses and elaborates on the status of phage therapy undergoing clinical trials, and the challenges encountered in their usage, and explores prospects in phage therapy research and application.
Phage and antibiotic combination therapy:feasibility and challenges

FENG Lu-yao,ZHU Xiao-fei,WU Zhong-wen,LI Lan-juan

DOI: https://doi.org/10.13381/j.cnki.cjm.202303020

2023-01-01

Abstract:Phage are viruses that specifically infect bacteria and have been used as antimicrobial agents since discovery.However, with the widespread use of antibiotics, phage therapy gradually faded into oblivion. At present, the emergence of antibiotic resistance （especially multi-drug resistance） seriously endangers the life and health of patients. Therefore, antibiotic resistance has become a global public health problem, which puts forward the necessity of finding new treatment methods. Long neglected in the West, phage therapy is regaining momentum. In this paper, we discussed some examples of phage and antibiotic combinations by examining a relatively large number of cases, at home and abroad, elaborated the feasibility of this dual therapy, and pointed out its challenges. In addition, we illustrated some possible mechanisms of the interaction between phages and antibiotics.
From forgotten cure to modern medicine: The resurgence of bacteriophage therapy

Tasnime Abdo Ahmad,Samar El Houjeiry,Souha S Kanj,Ghassan M Matar,Esber S Saba

DOI: https://doi.org/10.1016/j.jgar.2024.10.259

2024-10-31

Abstract:Objectives: The unregulated use of antibiotics has led to the rise of antibiotic-resistant bacterial strains. This study explores bacteriophage therapy as an alternative treatment, highlighting its history, significance, and advancements in Europe, the United States, and the Middle East. Methods: A comprehensive literature review on bacteriophage therapy was conducted, focusing on its development, clinical trials, and patient treatment applications. The study also examined challenges, limitations, criteria for ideal phage selection, and manipulation techniques. Results: The United States and several European countries have advanced in phage therapy, progressing from clinical trials to patient treatment, whereas Middle Eastern countries are still in the early stages. Bacteriophages offer specificity, abundance, and minimal side effects, but challenges like safety concerns and potential resistance limit their widespread use. Conclusion: Bacteriophage therapy shows promise as an antibiotic alternative but faces safety and resistance challenges. Continued research and better regulatory frameworks, especially in the Middle East, are needed to realize its potential.
Advocating for phage therapy

DOI: https://doi.org/10.1038/s41564-024-01733-7

IF: 28.3

2024-06-06

Nature Microbiology

Abstract:As antibiotic-resistant infections continue to rise globally, the development and application of phage therapy represents not only a promising but also a mandatory alternative approach to tackle this major public-health threat.

microbiology
Phage therapy: A novel approach against multidrug-resistant pathogens

Arushi Kapoor,Samriti Balaji Mudaliar,Vyasraj G. Bhat,Ishita Chakraborty,Alevoor Srinivas Bharath Prasad,Nirmal Mazumder

DOI: https://doi.org/10.1007/s13205-024-04101-8

IF: 2.893

2024-10-02

3 Biotech

Abstract:The rapid rise of multidrug-resistant (MDR) organisms has created a critical need for alternative treatment options. Phage therapy is gaining attention as an effective way to fight bacterial infections by using lytic bacteriophages to specifically target and kill harmful bacteria. This review discusses several phage therapeutic options and emphasizes new developments in phage biology. Phage treatment has proven to be successful against MDR bacteria, as evidenced by multiple human clinical trials that indicate favorable results in treating a range of diseases caused by these pathogens. Despite these promising results, challenges such as phage resistance, regulatory hurdles, and the need for standardized treatment protocols remain. To effectively combat MDR bacterial infections, future research must focus on enhancing phage effectiveness, guaranteeing safety for human usage and incorporating phage therapy into clinical practice.

biotechnology & applied microbiology
Current State of Compassionate Phage Therapy

Shawna McCallin,Jessica C. Sacher,Jan Zheng,Benjamin K. Chan,McCallin,Sacher,Zheng,Chan

DOI: https://doi.org/10.3390/v11040343

2019-04-12

Viruses

Abstract:There is a current unmet medical need for the treatment of antibiotic-resistant infections, and in the absence of approved alternatives, some clinicians are turning to empirical ones, such as phage therapy, for compassionate treatment. Phage therapy is ideal for compassionate use due to its long-standing historical use and publications, apparent lack of adverse effects, and solid support by fundamental research. Increased media coverage and peer-reviewed articles have given rise to a more widespread familiarity with its therapeutic potential. However, compassionate phage therapy (cPT) remains limited to a small number of experimental treatment centers or associated with individual physicians and researchers. It is possible, with the creation of guidelines and a greater central coordination, that cPT could reach more of those in need, starting by increasing the availability of phages. Subsequent steps, particularly production and purification, are difficult to scale, and treatment paradigms stand highly variable between cases, or are frequently not reported. This article serves both to synopsize cPT publications to date and to discuss currently available phage sources for cPT. As the antibiotic resistance crisis continues to grow and the future of phage therapy clinical trials remains undetermined, cPT represents a possibility for bridging the gap between current treatment failures and future approved alternatives. Streamlining the process of cPT will help to ensure high quality, therapeutically-beneficial, and safe treatment.
Bacteriophage–Host Interactions and the Therapeutic Potential of Bacteriophages

Leon M T Dicks,Wian Vermeulen,Leon M. T. Dicks

DOI: https://doi.org/10.3390/v16030478

2024-03-21

Viruses

Abstract:Healthcare faces a major problem with the increased emergence of antimicrobial resistance due to over-prescribing antibiotics. Bacteriophages may provide a solution to the treatment of bacterial infections given their specificity. Enzymes such as endolysins, exolysins, endopeptidases, endosialidases, and depolymerases produced by phages interact with bacterial surfaces, cell wall components, and exopolysaccharides, and may even destroy biofilms. Enzymatic cleavage of the host cell envelope components exposes specific receptors required for phage adhesion. Gram-positive bacteria are susceptible to phage infiltration through their peptidoglycan, cell wall teichoic acid (WTA), lipoteichoic acids (LTAs), and flagella. In Gram-negative bacteria, lipopolysaccharides (LPSs), pili, and capsules serve as targets. Defense mechanisms used by bacteria differ and include physical barriers (e.g., capsules) or endogenous mechanisms such as clustered regularly interspaced palindromic repeat (CRISPR)-associated protein (Cas) systems. Phage proteins stimulate immune responses against specific pathogens and improve antibiotic susceptibility. This review discusses the attachment of phages to bacterial cells, the penetration of bacterial cells, the use of phages in the treatment of bacterial infections, and the limitations of phage therapy. The therapeutic potential of phage-derived proteins and the impact that genomically engineered phages may have in the treatment of infections are summarized.

virology
Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy

Frank Oechslin

DOI: https://doi.org/10.3390/v10070351

2018-06-30

Viruses

Abstract:Bacteriophage (phage) therapy, i.e., the use of viruses that infect bacteria as antimicrobial agents, is a promising alternative to conventional antibiotics. Indeed, resistance to antibiotics has become a major public health problem after decades of extensive usage. However, one of the main questions regarding phage therapy is the possible rapid emergence of phage-resistant bacterial variants, which could impede favourable treatment outcomes. Experimental data has shown that phage-resistant variants occurred in up to 80% of studies targeting the intestinal milieu and 50% of studies using sepsis models. Phage-resistant variants have also been observed in human studies, as described in three out of four clinical trials that recorded the emergence of phage resistance. On the other hand, recent animal studies suggest that bacterial mutations that confer phage-resistance may result in fitness costs in the resistant bacterium, which, in turn, could benefit the host. Thus, phage resistance should not be underestimated and efforts should be made to develop methodologies for monitoring and preventing it. Moreover, understanding and taking advantage of the resistance-induced fitness costs in bacterial pathogens is a potentially promising avenue.

virology
Biological foundations of successful bacteriophage therapy

Carola Venturini,Aleksandra Petrovic Fabijan,Alicia Fajardo Lubian,Stefanie Barbirz,Jonathan Iredell

DOI: https://doi.org/10.15252/emmm.202012435

2022-05-28

EMBO Molecular Medicine

Abstract:This comprehensive review discusses bacterium–phage interactions, antimicrobial potential of phages and research challenges that impact realization of the successful bacteriophage therapy. Bacteriophages (phages) are selective viral predators of bacteria. Abundant and ubiquitous in nature, phages can be used to treat bacterial infections (phage therapy), including refractory infections and those resistant to antibiotics. However, despite an abundance of anecdotal evidence of efficacy, significant hurdles remain before routine implementation of phage therapy into medical practice, including a dearth of robust clinical trial data. Phage–bacterium interactions are complex and diverse, characterized by co‐evolution trajectories that are significantly influenced by the environments in which they occur (mammalian body sites, water, soil, etc.). An understanding of the molecular mechanisms underpinning these dynamics is essential for successful clinical translation. This review aims to cover key aspects of bacterium–phage interactions that affect bacterial killing by describing the most relevant published literature and detailing the current knowledge gaps most likely to influence therapeutic success.

medicine, research & experimental
Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis

Mario Cocorullo,Giovanni Stelitano,Laurent Robert Chiarelli

DOI: https://doi.org/10.3390/ijms25158321

2024-07-30

Abstract:Patients with cystic fibrosis (CF) are prone to developing life-threatening lung infections with a variety of pathogens that are difficult to eradicate, such as Burkholderia cepacia complex (Bcc), Hemophilus influenzae, Mycobacterium abscessus (Mab), Pseudomonas aeruginosa, and Staphylococcus aureus. These infections still remain an important issue, despite the therapy for CF having considerably improved in recent years. Moreover, prolonged exposure to antibiotics in combination favors the development and spread of multi-resistant bacteria; thus, the development of alternative strategies is crucial to counter antimicrobial resistance. In this context, phage therapy, i.e., the use of phages, viruses that specifically infect bacteria, has become a promising strategy. In this review, we aim to address the current status of phage therapy in the management of multidrug-resistant infections, from compassionate use cases to ongoing clinical trials, as well as the challenges this approach presents in the particular context of CF patients.
Phage Therapy Approaches to Reducing Pathogen Persistence and Transmission in Animal Production Environments: Opportunities and Challenges

Anna Colavecchio,Lawrence D Goodridge

DOI: https://doi.org/10.1128/microbiolspec.PFS-0017-2017

Abstract:The era of genomics has allowed for characterization of phages for use as antimicrobials to treat animal infections with a level of precision never before realized. As more research in phage therapy has been conducted, several advantages of phage therapy have been realized, including the ubiquitous nature, specificity, prevalence in the biosphere, and low inherent toxicity of phages, which makes them a safe and sustainable technology for control of animal diseases. These unique qualities of phages have led to several opportunities with respect to emerging trends in infectious disease treatment. However, the opportunities are tempered by several challenges to the successful implementation of phage therapy, such as the fact that an individual phage can only infect one or a few bacterial strains, meaning that large numbers of different phages will likely be needed to treat infections caused by multiple species of bacteria. In addition, phages are only effective if enough of them can reach the site of bacterial colonization, but clearance by the immune system upon introduction to the animal is a reality that must be overcome. Finally, bacterial resistance to the phages may develop, resulting in treatment failure. Even a successful phage infection and lysis of its host has consequences, because large amounts of endotoxin are released upon lysis of Gram-negative bacteria, which can lead to local and systemic complications. Overcoming these challenges will require careful design and development of phage cocktails, including comprehensive characterization of phage host range and assessment of immunological risks associated with phage treatment.
Current status of bacteriophage therapy for severe bacterial infections

Teiji Sawa,Kiyoshi Moriyama,Mao Kinoshita

DOI: https://doi.org/10.1186/s40560-024-00759-7

2024-11-03

Journal of Intensive Care

Abstract:The increase in the incidence of antibiotic-resistant bacteria poses a global public health threat. According to a 2019 WHO report, approximately 1.27 million deaths were attributed to antibiotic-resistant bacteria, with many cases linked to specific bacterial species, such as drug-resistant Pseudomonas aeruginosa and Staphylococcus aureus. By 2050, the number of deaths caused by these bacteria is predicted to surpass that caused by cancer. In response to this serious situation, phage therapy, an alternative to antibiotic treatment, has gained attention. Phage therapy involves the use of viruses that target specific bacteria to treat infections. This method has proven effective in multiple clinical cases, particularly for patients with severe infections caused by multidrug-resistant bacteria. For example, there are reports of patients with systemic infections caused by multidrug-resistant Acinetobacter who recovered following phage administration and patients infected with panresistant Pseudomonas aeruginosa who were cured by phage therapy. A key feature of phage therapy is its high specificity. Phages infect only specific bacteria and eliminate them. However, this specificity can also be a disadvantage, as careful selection of the appropriate phage for the target bacteria is needed. Additionally, bacteria can develop resistance to phages, potentially reducing treatment effectiveness over time. Efforts are underway to select, combine, and improve phages to address these challenges. In Belgium, a national phage bank has been established, and in the United States, the University of California, San Diego, has founded Innovative Phage Applications and Therapeutics (IPATH), marking significant progress toward the clinical application of phage therapy in the country. As a result, phage therapy is emerging as a component of personalized medicine, offering a new treatment option against antibiotic-resistant bacteria. The clinical application of phage therapy is particularly important in life-saving treatments for patients with severe bacterial infections, and its use in conjunction with antibiotics could enhance therapeutic outcomes. Continued research and development of this therapy could provide hope for many more patients in the future.

critical care medicine
Variable fitness effects of bacteriophage resistance mutations in Escherichia coli: implications for phage therapy

Baptiste Gaborieau,Raphaëlle Delattre,Sandrine Adiba,Olivier Clermont,Erick Denamur,Jean-Damien Ricard,Laurent Debarbieux

DOI: https://doi.org/10.1128/jvi.01113-24

IF: 6.549

2024-09-03

Journal of Virology

Abstract:ABSTRACT Bacteria exposed to bactericidal treatment, such as antibiotics or bacteriophages (phages), often develop resistance. While phage therapy is proposed as a solution to the antibiotic resistance crisis, the bacterial resistance emerging during phage therapy remains poorly characterized. In this study, we examined a large population of phage-resistant extra-intestinal pathogenic Escherichia coli 536 clones that emerged from both in vitro (non-limited liquid medium) and in vivo (murine pneumonia) conditions. Genome sequencing uncovered a convergent mutational pattern in phage resistance mechanisms under both conditions, particularly targeting two cell-wall components, the K15 capsule and the lipopolysaccharide (LPS). This suggests that their identification in vivo could be predicted from in vitro assays. Phage-resistant clones exhibited a wide range of fitness according to in vitro tests, growth rate, and resistance to amoeba grazing, which could not distinguish between the K15 capsule and LPS mutants. In contrast, K15 capsule mutants retained virulence comparable to the wild-type strain, whereas LPS mutants showed significant attenuation in the murine pneumonia model. Additionally, we observed that resistance to the therapeutic phage through a nonspecific mechanism, such as capsule overproduction, did not systematically lead to co-resistance to other phages that were initially capable or incapable of infecting the wild-type strain. Our findings highlight the importance of incorporating a diverse range of phages in the design of therapeutic cocktails to target potential future phage-resistant clones effectively. IMPORTANCE This study isolated more than 50 phage-resistant mutants from both in vitro and in vivo conditions, exposing an extra-intestinal pathogenic Escherichia coli strain to a single virulent phage. The characterization of these clones revealed several key findings: (1) mutations occurring during phage treatment affect the same pathways as those identified in vitro ; (2) the resistance mechanisms are associated with the modification of two cell-wall components, with one involving receptor deletion (phage-specific mechanism) and the other, less frequent, involving receptor masking (phage-nonspecific mechanism); (3) an in vivo virulence assay demonstrated that the absence of the receptor abolishes virulence while masking the receptor preserves it; and (4) clones with a resistance mechanism nonspecific to a particular phage can remain susceptible to other phages. This supports the idea of incorporating diverse phages into therapeutic cocktails designed to collectively target both wild-type and phage-resistant strains, including those with resistance mechanisms nonspecific to a phage.

virology
Phage-Based Therapy in Combination with Antibiotics: A Promising Alternative against Multidrug-Resistant Gram-Negative Pathogens

Cleo Anastassopoulou,Stefanos Ferous,Aikaterini Petsimeri,Georgia Gioula,Athanasios Tsakris

DOI: https://doi.org/10.3390/pathogens13100896

IF: 3.7

2024-10-15

Pathogens

Abstract:The continued rise in antimicrobial resistance poses a serious threat to public health worldwide. The use of phages that can have bactericidal activity without disrupting the normal flora represents a promising alternative treatment method. This practice has been successfully applied for decades, mainly in Eastern Europe, and has recently been used as an emergency therapy for compassionate care in the United States. Here, we provide a comprehensive review of the pre-clinical and clinical applications of phage therapy concerning three major Gram-negative pathogens: Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. The advantages and the challenges of expanding the usage of phages as an alternative or adjunctive treatment for antimicrobial-resistant bacterial infections are discussed. We emphasize the virologic complexities of using the highly adaptable phage populations as molecular tools, along with antibiotic chemical compounds, to effectively combat rapidly coevolving pathogenic bacteria in the host microenvironment. Pre-clinical studies, isolated clinical reports and a few randomized clinical trials have shown that bacteriophages can be effective in treating multidrug-resistant bacterial infections. The ability of some phages to revert the resistance against antibiotics, and possibly also against the human complement and other phages, appears to be a great advantage of phage therapy despite the inevitable emergence of phage-resistant strains. Bacteriophages (or specific phage-derived products) can enhance antimicrobial efficacy by reducing bacterial virulence via the alteration of basic bacterial structures, primarily of the cellular wall and membrane. Although several issues remain open regarding their effective clinical application, it appears that phage-based therapeutics in combination with antibiotics can provide an effective solution to the spread of antimicrobial resistance.

microbiology

Phage therapy in noncommunicable diseases

Thromboxane a2: biosynthesis and effects on platelets.

Phage Therapy: A Different Approach to Fight Bacterial Infections

Phage therapy in gut microbiome

Phage therapy: From biological mechanisms to future directions

Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation

Bacteriophages as Alternatives to Antibiotics in Clinical Care

Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens

Phage and antibiotic combination therapy:feasibility and challenges

From forgotten cure to modern medicine: The resurgence of bacteriophage therapy

Advocating for phage therapy

Phage therapy: A novel approach against multidrug-resistant pathogens

Current State of Compassionate Phage Therapy

Bacteriophage–Host Interactions and the Therapeutic Potential of Bacteriophages

Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy

Biological foundations of successful bacteriophage therapy

Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis

Phage Therapy Approaches to Reducing Pathogen Persistence and Transmission in Animal Production Environments: Opportunities and Challenges

Current status of bacteriophage therapy for severe bacterial infections

Variable fitness effects of bacteriophage resistance mutations in Escherichia coli: implications for phage therapy

Phage-Based Therapy in Combination with Antibiotics: A Promising Alternative against Multidrug-Resistant Gram-Negative Pathogens